First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Forte Biosciences, Inc.

    FBRX · 2 developments mapped · last assessed 2026-08-27

    Market Ontology has mapped 2 macro, policy, and market developments to Forte Biosciences, Inc. since 2026-08-19. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for FBRX yet, so no modelled value is shown. The FBRX valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run FBRX on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for FBRX. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Open question

      Forte Biosciences, Inc. Files Recommendation Statement Regarding Third-Party Tender Offer

      Direct impact on share price due to tender offer premium and potential acquisition completion. Uncertainty regarding the offer's success or competing bids.

      · Moves probability of acquisition completion, acquisition premium, future growth prospects if acquisition fails

    What changed, by assumption

    Probability of acquisition completion
    • 2026-08-19Forte Biosciences, Inc. Files Recommendation Statement Regarding Third-Party Tender Offer
    Future growth rates
    • 2026-08-27Forte Biosciences, Inc. Completes Acquisition or Disposition of Assets

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-08-27Share countBullishStock component of consideration dilutes existing acquirer holders.0.70
    2026-08-27Net debtBullishCash component of consideration is typically debt-funded, raising net debt.0.70
    2026-08-27RevenueBullishAcquisition adds target revenue to acquirer P&L on close.0.70
    2026-08-24Terminal growthBearishGuggenheim Securities used an illustrative perpetual growth rate of negative 50.0%, reflecting continued decline in revenue following assumed global loss of exclusivity for FB102 in 2043.1.00
    2026-08-24Cost of capitalBullishGuggenheim Securities used a discount rate range of 11.75% - 14.50% based on its estimate of the Company’s weighted average cost of capital.1.00
    2026-08-06Net debtBearishLiability-management transactions often reduce gross debt or push maturities out.0.70
    2026-08-06Interest expenseBearishTender/exchange extends maturity profile and typically lowers near-term interest expense.0.70
    2026-07-27Valuation multipleBullishTarget re-rates to bid premium until close.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-08-27Forte Biosciences, Inc. Completes Acquisition or Disposition of Assetsmixed1-3m0.70
    2026-08-19Forte Biosciences, Inc. Files Recommendation Statement Regarding Third-Party Tender Offermixed1-3m0.90